Register Login
Register to leave comments
  • News bot Aug. 17, 2026, 1:06 p.m.

    📋 BRIDGEBIO PHARMA, INC. (BBIO) - Clinical Trial Update

    Filing Date: 2026-08-17

    Accepted: 2026-08-17 09:05:22

    Event Type: Clinical Trial Update

    Event Details:

    BRIDGEBIO PHARMA, INC. (BBIO) Announces Clinical Trial Update BRIDGEBIO PHARMA, INC. (BBIO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: medicines, managers
    • Diseases/Conditions: genetic conditions
    • Collaboration: LLC

    🔬 Clinical Development Pipeline (BRIDGEBIO PHARMA, INC.):

    Product Type Development Stage Therapeutic Area Source
    Acoramidis (AG10) Other Phase PHASE3 Amyloidosis in Transthyretin (TTR) ClinicalTrials.gov
    Placebo oral tablet Other Phase PHASE3 Amyloidosis ClinicalTrials.gov
    Acoramidis Other Phase PHASE3 Amyloidosis ClinicalTrials.gov
    Acoramidis (AG10) oral tablet Other Phase PHASE4 Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) ClinicalTrials.gov
    Standard of Care Other Phase PHASE3 Autosomal Dominant Hypocalcemia (ADH) ClinicalTrials.gov
    Encaleret Other Phase PHASE3 Autosomal Dominant Hypocalcemia (ADH) ClinicalTrials.gov
    AI Toolkit for ATTR-CM Diagnosis Other Preclinical Transthyretin (TTR) Amyloid Cardiomyopathy ClinicalTrials.gov
    ATTR-CM AI-ECG and AI-Echo Model Other Preclinical ATTR Amyloidosis With Cardiomyopathy ClinicalTrials.gov
    infigratinib 0.25 mg/kg/day Other Phase PHASE2 Hypochondroplasia ClinicalTrials.gov
    infigratinib 0.128 mg/kg/day Other Phase PHASE2 Hypochondroplasia ClinicalTrials.gov
    Bevacizumab Other Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    FOLFOX Other Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    Ribociclib Other Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    Fulvestrant Other Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    Trastuzumab Other Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    BBO-10203 Other Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    Infigratinib is provided as sprinkle capsules for daily oral administration Other Phase PHASE2 Achondroplasia ClinicalTrials.gov
    Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration Other Phase PHASE2 Achondroplasia ClinicalTrials.gov
    Infigratinib is provided as a single dose of minitablets for oral administration Other Phase PHASE2 Achondroplasia ClinicalTrials.gov
    ALXN2060 Other Phase PHASE3 Symptomatic Transthyretin Amyloid Cardiomyopathy ClinicalTrials.gov
    Nab-paclitaxel Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Gemcitabine Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    mFOLFIRINOX Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    mFOLFOX6 Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Cetuximab Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Pemetrexed Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Platinum chemotherapy (cisplatin or carboplatin) Drug Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Pembrolizumab Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    BBO-11818 Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    Infigratinib Other Phase PHASE2 Hypochondroplasia ClinicalTrials.gov
    BBO-8520 Other Phase PHASE1 Non-small Cell Lung Cancer ClinicalTrials.gov
    sotorasib Other Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    BBP-398 Other Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    Placebo Other Phase PHASE1 Healthy ClinicalTrials.gov
    BBP-711 Other Phase PHASE1 Healthy ClinicalTrials.gov
    VT30 Other Phase PHASE1 Venous Malformation ClinicalTrials.gov
    AG10 Other Phase PHASE2 Familial ATTR-CM (ATTRm-CM, or FAC) ClinicalTrials.gov
    PTR-01 Other Phase PHASE2 Recessive Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    BGJ398 (infigratinib) Other Phase PHASE2 Advanced Cholangiocarcinoma ClinicalTrials.gov
    BBP-671 Other Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Cisplatin Other Phase PHASE3 Advanced Cholangiocarcinoma ClinicalTrials.gov
    BGJ398 Other Phase PHASE3 Advanced Cholangiocarcinoma ClinicalTrials.gov
    AG10 oral tablet Other Phase PHASE1 Amyloid Cardiomyopathy, Transthyretin-Related ClinicalTrials.gov
    99mTc-pyrophosphate Scintigraphy Other Approved Transthyretin Amyloidosis ClinicalTrials.gov
    BBP-398 with nivolumab Other Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    BBP-398 (Formerly known as IACS-15509) Other Phase PHASE1 Tumor, Solid ClinicalTrials.gov
    Infigratinib 0.25 mg/kg Other Phase PHASE2 Achondroplasia ClinicalTrials.gov
    Infigratinib 0.128 mg/kg Other Phase PHASE2 Achondroplasia ClinicalTrials.gov
    Infigratinib 0.064 mg/kg Other Phase PHASE2 Achondroplasia ClinicalTrials.gov
    Infigratinib 0.032 mg/kg Other Phase PHASE2 Achondroplasia ClinicalTrials.gov
    Infigratinib 0.016 mg/kg Other Phase PHASE2 Achondroplasia ClinicalTrials.gov
    Cardiac amyloidosis deep learning model Other Approved Cardiac Amyloidosis ClinicalTrials.gov
    Computed tomography (CT) Other Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Iopamidol Other Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Omnipaque 350 Other Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Tamoxifen Other Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Placebo Comparator 0.25 mg/kg/day Other Phase PHASE3 Achondroplasia ClinicalTrials.gov
    NALIRIFOX Other Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: BRIDGEBIO PHARMA, INC.
    • Ticker Symbol: BBIO

Search

News categories